Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 2013

View Archived Issues

Phase I data presented for RPC-1063 in IBD patients

Complementary biomarker for the diagnosis of gastrointestinal carcinoma described

Partnership to advance fusion protein for NHL

Results presented for Pulmagen's lead oral DP2 receptor antagonist ADC-3680

Blood thiamine metabolism as a non-invasive biomarker for AD diagnosis

HGT-1410 demonstrates rapid systemic distribution in vivo

New inhibitors of phosphate transport synthesized by Astellas

Merck & Co. patents novel GPR119 receptor agonists

Canadian group discloses new CBX2 modulators for cancer

Novel FABP inhibitors divulged by Roche

Merck & Co. presents novel bacterial vaccines

Companies announce termination of QVAR comarketing agreement

Rigel Pharmaceuticals set to advance to phase II trial for dry eye disease therapeutic

Scientists at Merck & Co. synthesize novel gamma-secretase modulators

HbA1c test receives marketing approval in U.S. for diabetes diagnosis

TauRx Therapeutics opens U.K. sites in phase III trials of LMTX

Bayer Yakuhin launches Stivarga tablets in Japan

Merck & Co. discontinues development of preladenant for Parkinson's disease

PharmaMar studies PM-01183 in combination with capecitabine

Nippon Shinyaku launches Regtect in Japan

Mitsubishi Tanabe Pharma seeks Japanese approval of canagliflozin

OncoTherapy Science obtains rights to results of collaborative research with Kumamoto University

Data show GCS-100 may improve renal function

Astellas submits marketing application in Japan for enzalutamide

Dosing begins in phase I trial of SB-9200 in HCV infection

Headline results reported from phase IIIa trial of liraglutide for obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...